| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 3,040 | -165,714 | -69,461 | -87,911 |
| Depreciation and amortization | 21,074 | 20,995 | 21,033 | 42,135 |
| Premium deficiency reserve | -4,715 | 55,414 | -23,736 | -12,929 |
| Paid in-kind interest expense | 10,799 | 9,905 | 19,813 | NaN |
| Amortization of original issue discount and debt issuance costs | 2,803 | 2,173 | 10,981 | 402 |
| Equity-based compensation | 1,051 | 1,099 | 1,211 | 3,271 |
| Provision for bad debts | NaN | 2,996 | NaN | NaN |
| Gain (loss) on disposition of property plant equipment, excluding oil and gas property and timber property | NaN | 178 | -340 | NaN |
| Impairment of assets held for sale | NaN | 0 | NaN | NaN |
| Gain on write off of contingent consideration | NaN | 0 | 0 | NaN |
| Deferred income taxes | 478 | 2,868 | NaN | NaN |
| Mark-to-market adjustment of stock warrants | -330 | -5,066 | 2,540 | -5,324 |
| Health plan receivable | 32,436 | 10,565 | -11,439 | -27,803 |
| Clinic fees, insurance, and other receivable | 5,681 | 2,506 | -3,834 | 3,625 |
| Prepaid expenses and other current assets | 715 | 32 | -4,762 | 1,747 |
| Other long-term assets | 473 | -8,749 | -2,190 | 14,464 |
| Accounts payable, accrued expenses, and other current liabilities | 420 | 3,322 | 1,586 | 6,200 |
| Accrued payroll | 823 | 601 | 187 | -1,560 |
| Health plan settlements payable | -21,585 | 16,350 | 11,609 | -13,694 |
| Claims payable | -1,892 | 34,126 | -2,373 | 948 |
| Accrued interest | 0 | 158 | -12,653 | 10,619 |
| Other long-term liabilities | NaN | 0 | NaN | NaN |
| Operating lease liability | -128 | -422 | 1,286 | -223 |
| Net cash used in operating activities | -27,467 | -25,727 | -15,412 | -50,099 |
| Purchases of property and equipment | NaN | -198 | 119 | NaN |
| Proceeds from asset sale | NaN | 0 | 0 | 50 |
| Other, net | 43 | NaN | NaN | NaN |
| Proceeds from liability-classified warrants and private placement offering, net of offering costs paid | NaN | 0 | 0 | 0 |
| Net cash used in investing activities | -43 | 198 | -119 | 50 |
| Proceeds from at-the-market sales, net of offering costs paid | NaN | 0 | 0 | 0 |
| Proceeds from long-term debt, net of original issue discount | 27,000 | 13,000 | 15,000 | 45,000 |
| Deferred offering costs paid | NaN | 0 | 0 | 0 |
| Payment of tax withholdings upon settlement of restricted stock unit awards | NaN | 0 | 0 | 0 |
| Proceeds from short-term debt | 1,044 | 0 | 0 | 1,137 |
| Repayment of short-term and long-term debt | 209 | 114 | 341 | 682 |
| Payment of debt issuance costs | 30 | 12 | -7 | 181 |
| Net cash provided by financing activities | 27,805 | 12,874 | 14,666 | 45,274 |
| Net change in cash and restricted cash | 295 | -12,655 | -865 | -4,775 |
| Cash and restricted cash, beginning of period | 25,807 | 38,462 | 44,102 | NaN |
| Cash and restricted cash, end of period | 26,102 | 25,807 | 38,462 | NaN |
P3 Health Partners Inc. (PIII)
P3 Health Partners Inc. (PIII)